Navigation Links
Franklin & Seidelmann Publishes Complex Podiatry MRI Study
Date:3/11/2008

Subspecialty Teleradiology Model Accelerates Study Conclusions

CLEVELAND, March 11 /PRNewswire/ -- Franklin & Seidelmann Subspecialty Radiology (F&S) announced that it recently completed a complex podiatry study that was published in the March, 2008 issue of the journal Skeletal Radiology. Because of its subspecialty teleradiology model, which aggregates a high volume of MRI interpretations coupled with specialized podiatry expertise, F&S was able to complete the study in just a few months rather than the years that would be required in a traditional radiology environment.

The scientific article, "Plantar fasciitis and calcaneal spur formation are associated with abductor digiti minimi atrophy on MRI of the foot," describes a study conducted from August 2006 to January 2007 with 200 patients of all ages from 40 states referred for an MRI of the hindfoot due to the presence of heel pain.

Study conclusions showed a significant association between atrophy of the abductor digit minimi muscle, an MRI manifestation of Baxter's neuropathy, with age, plantar calcaneal spur formation and plantar fasciitis. These findings support the notion of an etiologic role for compression of the inferior calcaneal nerve as it passes anterior to the medial calcaneal tuberosity in the development of Baxter's neuropathy.

"Heel pain is very common yet not well understood, and the significance of the study proved that MRI can be a useful diagnostic tool when done prior to a surgical procedure in order to better define the patient's problem and potentially alter the surgery or patient expectations," said Dr. Javier Beltran, American Board of Radiology Certified Radiologist and Musculoskeletal MRI Specialist with Franklin & Seidelmann. Beltran also is the current chairman of the Department of Radiology at Maimonides Medical Center, Brooklyn, NY and a Clinical Professor of Radiology at the Mount Sinai School of Medicine, New York, NY.

"The sheer numbe
'/>"/>

SOURCE Franklin & Seidelmann Subspecialty Radiology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
2. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
3. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
6. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
7. Northwestern Memorial Study Tests Cancer Drug on Scleroderma Patients
8. Bertrand Study Finds Significant Value in Breast-Specific Gamma Imaging (BSGI) as an Adjunctive Procedure in Breast Diagnostics
9. Study Finds Starion Instruments Tissue Welding Technology Safe and Effective in Parotidectomy Procedures
10. Thomson Healthcare Cancer Profiler Used in Study
11. Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...e/ -- Reportlinker.com announces that a new market..., Mammography Equipment - A Global Market Pers...330/Mammography-Equipment---A-Global-Market-Perspe...r in industrialized as well as developing nations ...mmography market. Globally, escalating awareness a...
(Date:11/25/2009)...Newswire/ -- Cempra Pharmaceuticals Inc. today ann...hief executive officer, will present at the Piper ... a.m. EST, December 1, 2009, at The New York Palac...ide an overview of the company,s two leading antib...resistant pathogens including MRSA. ,, About C...
(Date:11/25/2009)...ewswire/ -- ChemoCentryx, Inc., announced today ... PROTECT-1 (the Prospective Randomized Oral Therap...-EN(TM) (CCX282-B) in patients with moderate-to-se...y with a favorable safety and tolerability profile...icacy in the reduction of disease severity as defi...
Breaking Medicine Technology:Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 1FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 2FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 3FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 4FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 5FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 6FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 7FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 8PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear Nose and Throat Market 5231 1PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear Nose and Throat Market 5231 2PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear Nose and Throat Market 5231 3Kimberly Clark Acquires Baylis Medical Companys Pain Management Business 5227 1Kimberly Clark Acquires Baylis Medical Companys Pain Management Business 5227 2Kimberly Clark Acquires Baylis Medical Companys Pain Management Business 5227 3
...ain cell that was long overlooked by researchers e...ain differs fundamentally from that of a mouse or ...findings as the cover story in the March 11 issue ...at the University of Rochester Medical Center fo...ought simply to support flashier brain cells known...
.../ -- Results from the Phase II portion of a Phas...nal drug relaxin for the treatment of acute heart ...day, March 29, at the American College of Cardiolo...do, Fla. , , John R. Teerlink, M.D., professor of... , Director of Heart Failure, San Francisco Vetera...
Other Medicine Technology:Astrocytes Help Separate Man From Mouse 2Astrocytes Help Separate Man From Mouse 3Astrocytes Help Separate Man From Mouse 4Astrocytes Help Separate Man From Mouse 5Results From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session 2
(Date:11/27/2009)...Mass., Nov. 27 GSI Group...ier of precision technology products and semicondu...ng of the Company,s shareholders has been schedule...on of the meeting will be announced in due course....requisition notice from Stephen Bershad, a holder ...
(Date:11/27/2009)...CO, Nov. 27 The Gymboree... Lambert, CFO/COO, will present at the NASDAQ OMX ...ay Fair Hotel in London, England, on Wednesday, De... to a live broadcast of The Gymboree Corporation,s...www.gymboree.com, click on "Our Company" at the bo...
(Date:11/27/2009)... XenaCare Holdings has announced that it has be...n, one of the largest nonprofit organizations dedi...ation. , Delray Beach, FL...nc. (OTCBB: XCHO), a company specializing in the m...hcare products, has announced today that is has be...
(Date:11/27/2009)... Voyant Health™ announced today that Spec...its TraumaCad Enterprise orthopedic templating sol... , (PRWEB) November 27, 20...ectrum Health (Grand Rapids, Michigan) has license...olution and its TraumaCad Extend workflow solution...
(Date:11/26/2009)...Nov. 27 With cold and flu season u...od practices to control the spread of infections a...ot only to keep ourselves healthy, but to avoid tr...erty, RN, MS, CIC (certified in infection-control)...ational health at Hospital for Special Surgery (HS...
Breaking Medicine News(10 mins):Health News:GSI Group Calls Shareholders Meeting 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4
...riods of blocked blood flow may be better conditio...cording to new research from the University of Cin... UC surgeon-scientist Karyn Butler, MD, found that...yknown as JAK-STATthat protects the heart muscle. ...
...,CVD) today announced that it will present at the ...ary 7 at 7:30 pm ET. Investors may access a,live w...com . In order to register,and download any necess...ive drug development services companies,with reven...
...he gym , , SATURDAY, Jan. 5 (HealthDay New...esolution list, and you don,t even need a gym memb... the correct home equipment, being creative and bo... is to lose weight, but it should not necessarily ...
....,Calvin B. Johnson today invited all Pennsylvania... exhibit at the Farm Show for free health,screenin... information., "Our Body Shop is a fun place for ...n staying fit, preventing,injuries, and detecting ...
...ional group,purchasing organization for the health...o Nonin Medical, Inc. Each year, Amerinet recogniz...nd services to health care,providers across the na...g to millions of people worldwide., "The Niche Su...
...cientists say , , FRIDAY, Jan. 4 (HealthDa...arkinson,s disease may be triggered by a harmful m...w research reveals. , The modification in question...earchers say. , The change short-circuits a proces...
Other Medicine News:Health News:Mini 'stress tests' could help condition heart to survive major attack 2Health News:Fitness Begins at Home 2Health News:Nonin Medical is Honored With Niche Supplier Award from Amerinet 2Health News:Research Gets Closer to Origin of Parkinson's Disease 2Health News:Research Gets Closer to Origin of Parkinson's Disease 3
MIS Distal Femoral Alignment/Saw Guide and Intramedullary Rod
Ascent Anterior Referencing Femoral Instrument Case
Ascent Knee System Case # 2
Lineage Acetabular Cup System (Ceramic)
Medicine Products: